A systems biology perspective on cholangiocellular carcinoma development: Focus on MAPK-signaling and the extracellular environment

Journal of Hepatology

Volumn 50, Issue 6, 2009, Pages 1122-1131

  Wang, Chunxia ^a   Maass, Thorsten ^b   Krupp, Markus ^b   Thieringer, Florian ^b   Strand, Susanne ^b   Wörns, Marcus A ^b   Barreiros, Ana Paula ^b   Galle, Peter R ^b   Teufel, Andreas ^b  

^a SHANDONG PROVINCIAL HOSPITAL AFFILIATED TO SHANDONG UNIVERSITY   (China)

^b JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

Bioinformatics; Cholangiocarcinoma; Liver cancer; Oncogenomics; Systems biology

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE; SORAFENIB;

ARTICLE; BILE DUCT CARCINOMA; CANCER GENETICS; CANCER GROWTH; CELL CYCLE REGULATION; EXTRACELLULAR MATRIX; GENETIC ASSOCIATION; GENETIC TRANSCRIPTION; HUMAN; KNOCKOUT MOUSE; LIVER CELL CARCINOMA; MEDLINE; MICROARRAY ANALYSIS; MICROENVIRONMENT; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

ANIMALS; ANTINEOPLASTIC AGENTS; BENZENESULFONATES; BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; CHOLANGIOCARCINOMA; COMPUTATIONAL BIOLOGY; DATABASES, GENETIC; EVOLUTION; EXTRACELLULAR SPACE; HUMANS; MAP KINASE SIGNALING SYSTEM; MICE; MULTIGENE FAMILY; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PYRIDINES; SYSTEMS BIOLOGY;

EID: 67349283061     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2009.01.024     Document Type: Article

References (40)

1. Khan S.A., Thomas H.C., Davidson B.R., and Taylor-Robinson S.D. Cholangiocarcinoma. Lancet 366 (2005) 1303-1314
2. Shaib Y.H., Davila J.A., McGlynn K., and El-Serag H.B. Rising incidence of intrahepatic cholangiocarcinoma in the United States: a true increase?. J Hepatol 40 (2004) 472-477
3. Shaib Y., and El-Serag H.B. The epidemiology of cholangiocarcinoma. Semin Liver Dis 24 (2004) 115-125
4. Ben-Menachem T. Risk factors for cholangiocarcinoma. Eur J Gastroenterol Hepatol 19 (2007) 615-617
5. Shimoda M., and Kubota K. Multi-disciplinary treatment for cholangiocellular carcinoma. World J Gastroenterol 13 (2007) 1500-1504
6. Zhu A.X. Development of sorafenib and other molecularly targeted agents in hepatocellular carcinoma. Cancer 112 (2008) 250-259
7. Teufel A., Weinmann A., Krupp M., Budinger M., and Galle P.R. Genome-wide analysis of factors regulating gene expression in liver. Gene 389 (2007) 114-121
8. Teufel A., Krupp M., Weinmann A., and Galle P.R. Current bioinformatics tools in genomic biomedical research (Review). Int J Mol Med 17 (2006) 967-973
9. Sakatani T., and Onyango P. Oncogenomics: prospects for the future. Expert Rev Anticancer Ther 3 (2003) 891-901
10. Hernandez P., Huerta-Cepas J., Montaner D., Al-Shahrour F., Valls J., Gomez L., et al. Evidence for systems-level molecular mechanisms of tumorigenesis. BMC Genomics 8 (2007) 185
11. Wheeler D.L., Barrett T., Benson D.A., Bryant S.H., Canese K., Chetvernin V., et al. Database resources of the National Center for Biotechnology Information. Nucleic Acids Res 35 (2007) D5-D12
12. Obama K., Ura K., Li M., Katagiri T., Tsunoda T., Nomura A., et al. Genome-wide analysis of gene expression in human intrahepatic cholangiocarcinoma. Hepatology 41 (2005) 1339-1348
13. Zhang B., Kirov S., and Snoddy J. WebGestalt: an integrated system for exploring gene sets in various biological contexts. Nucleic Acids Res 33 (2005) W741-W748
14. Lee J.S., Heo J., Libbrecht L., Chu I.S., Kaposi-Novak P., Calvisi D.F., et al. A novel prognostic subtype of human hepatocellular carcinoma derived from hepatic progenitor cells. Nat Med 12 (2006) 410-416
15. Lee J.S., and Thorgeirsson S.S. Comparative and integrative functional genomics of HCC. Oncogene 25 (2006) 3801-3809
16. Ashburner M., Ball C.A., Blake J.A., Botstein D., Butler H., Cherry J.M., et al. Gene ontology: tool for the unification of biology. The gene ontology consortium. Nat Genet 25 (2000) 25-29
17. http://www.medicalgenomics.org/databases/loga/news.
18. Hsu C.N., Lai J.M., Liu C.H., Tseng H.H., Lin C.Y., Lin K.T., et al. Detection of the inferred interaction network in hepatocellular carcinoma from EHCO (Encyclopedia of Hepatocellular Carcinoma genes Online). BMC Bioinformatics 8 (2007) 66
19. Ogata H., Goto S., Sato K., Fujibuchi W., Bono H., and Kanehisa M. KEGG: Kyoto Encyclopedia of Genes and Genomes. Nucleic Acids Res 27 (1999) 29-34
20. Biocarta. http://www.biocarta.com.
21. Pimienta G., and Pascual J. Canonical and alternative MAPK signaling. Cell Cycle 6 (2007) 2628-2632
22. Ferrajoli A., Faderl S., Ravandi F., and Estrov Z. The JAK-STAT pathway: a therapeutic target in hematological malignancies. Curr Cancer Drug Targets 6 (2006) 671-679
23. Kowanetz M., and Ferrara N. Vascular endothelial growth factor signaling pathways: therapeutic perspective. Clin Cancer Res 12 (2006) 5018-5022
24. Mamane Y., Petroulakis E., LeBacquer O., and Sonenberg N. mTOR, translation initiation and cancer. Oncogene 25 (2006) 6416-6422
25. Krishnan J., Selvarajoo K., Tsuchiya M., Lee G., and Choi S. Toll-like receptor signal transduction. Exp Mol Med 39 (2007) 421-438
26. Geisler C. TCR trafficking in resting and stimulated T cells. Crit Rev Immunol 24 (2004) 67-86
27. Gavert N., and Ben-Ze'ev A. beta-Catenin signaling in biological control and cancer. J Cell Biochem 102 (2007) 820-828
28. Roux P.P., and Blenis J. ERK and p38 MAPK-activated protein kinases: a family of protein kinases with diverse biological functions. Microbiol Mol Biol Rev 68 (2004) 320-344
29. Ohashi K., Nakajima Y., Kanehiro H., Tsutsumi M., Taki J., Aomatsu Y., et al. Ki-ras mutations and p53 protein expressions in intrahepatic cholangiocarcinomas: relation to gross tumor morphology. Gastroenterology 109 (1995) 1612-1617
30. Isa T., Tomita S., Nakachi A., Miyazato H., Shimoji H., Kusano T., et al. Analysis of microsatellite instability, K-ras gene mutation and p53 protein overexpression in intrahepatic cholangiocarcinoma. Hepatogastroenterology 49 (2002) 604-608
31. Rashid A., Ueki T., Gao Y.T., Houlihan P.S., Wallace C., Wang B.S., et al. K-ras mutation, p53 overexpression, and microsatellite instability in biliary tract cancers: a population-based study in China. Clin Cancer Res 8 (2002) 3156-3163
32. Tannapfel A., Sommerer F., Benicke M., Katalinic A., Uhlmann D., Witzigmann H., et al. Mutations of the BRAF gene in cholangiocarcinoma but not in hepatocellular carcinoma. Gut 52 (2003) 706-712
33. Abraham S.M., and Clark A.R. Dual-specificity phosphatase 1: a critical regulator of innate immune responses. Biochem Soc Trans 34 (2006) 1018-1023
34. Yang S.S., Van Aelst L., and Bar-Sagi D. Differential interactions of human Sos1 and Sos2 with Grb2. J Biol Chem 270 (1995) 18212-18215
35. Wilhelm S.M., Carter C., Tang L., Wilkie D., McNabola A., Rong H., et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 64 (2004) 7099-7109
36. Huether A., Hopfner M., Baradari V., Schuppan D., and Scherubl H. Sorafenib alone or as combination therapy for growth control of cholangiocarcinoma. Biochem Pharmacol 73 (2007) 1308-1317
37. Lomax J. Get ready to GO! A biologist's guide to the Gene Ontology. Brief Bioinform 6 (2005) 298-304
38. Tlsty T.D., and Coussens L.M. Tumor stroma and regulation of cancer development. Annu Rev Pathol 1 (2006) 119-150
39. Karnoub A.E., Dash A.B., Vo A.P., Sullivan A., Brooks M.W., Bell G.W., et al. Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature 449 (2007) 557-563
40. Lukashev M.E., and Werb Z. ECM signalling: orchestrating cell behaviour and misbehaviour. Trends Cell Biol 8 (1998) 437-441